Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPN305-102 Part B 12-month follow-up
NL-OMON45118Phase 2Active, not recruiting
- Sponsor
- Opsona Therapeutics
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in delayed graft function (DGF) comparing Prior OPN-305 arm with Prior placebo arm (2 arms). Primary endpoints: Incidence of biopsy-proven allograft rejection or graft loss, Initiation and frequency of dialysis or other renal replacement therapy and 4 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
tomaralimab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NL-OMON45118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45118.